---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-001435"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:38:59.256987+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences doses first patients in Phase 1b PRECISE-AD trial of PMN310 for Alzheimer's disease

## Summary
- First patients dosed in Phase 1b PRECISE-AD trial evaluating PMN310, a humanized mAb targeting toxic Aβ oligomers.
- Interim six-month results expected in 1H 2026; topline results anticipated in 2H 2026.
- PMN310 selectively targets soluble amyloid-beta oligomers, avoiding monomers and plaques, potentially differentiating from current AD therapies.
- Rapid enrollment underscores unmet need for better AD treatments; investigators note need for effective and well-tolerated options.

## SEC filing metadata
- accession: 0001558370-25-001435
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837025001435/0001558370-25-001435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837025001435/pmn-20250225x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-001435
- JSON: https://secwatch.observer/filing/0001558370-25-001435.json
- Plain text: https://secwatch.observer/filing/0001558370-25-001435.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.